Chemical Property of CID 11145434
Chemical Property:
- Appearance/Colour:White to off-white crystalline powder
- Vapor Pressure:1.25E-24mmHg at 25°C
- Melting Point:143-144.5°C
- Boiling Point:765.3 °C at 760 mmHg
- PKA:pKa1 3.0; pKa2 (25°) 5.4
- Flash Point:416.7 °C
- PSA：170.54000
- LogP:1.64520
- Storage Temp.:-20°C Freezer
- Solubility.:methanol: ≥50 mg/mL, clear, colorless to yellow
- Water Solubility.:Soluble in water, methanol, and ethanol.
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:9
- Rotatable Bond Count:10
- Exact Mass:492.21078060
- Heavy Atom Count:35
- Complexity:627
- Purity/Quality:
-
99%, *data from raw suppliers
(S,S,S)-EnalaprilMaleate *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xi
- Hazard Codes:Xi,Xn
- Statements:
36/37/38-62-63
- Safety Statements:
22-24/25-36/37-26
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CCOC(=O)C(CCC1=CC=CC=C1)[NH2+]C(C)C(=O)[NH+]2CCCC2C(=O)O.C(=CC(=O)[O-])C(=O)[O-]
- Isomeric SMILES:CCOC(=O)[C@H](CCC1=CC=CC=C1)[NH2+][C@@H](C)C(=O)[NH+]2CCC[C@H]2C(=O)O.C(=C\C(=O)[O-])\C(=O)[O-]
-
Description
Enalapril maleate is the second angiotensin converting enzyme inhibitor to reach
the marketplace. Like captopril, the first entry in this area, enalapril is useful in
the treatment of hypertension and congestive heart failure. It has a longer effective
half-life than captopril, allowing once or twice-daily dosing, and appears to have a
somewhat lower incidence of side effects.
-
Uses
Enalapril maleate salt is used as a long-acting ACE inhibitor and antihypertensive, used to study diabetic angiopathy in diabetic rats and inhibition of ACE in hog plasma (I50=1.2nM). ACE inhibitors disturb the enin-angiotensin- aldosterone system. Additional ACE inhibitors include: Enalapril, Enalaprilat dihydrate, Enalaprilat, and Enalapril-d5 Maleate Salt, among others. An antihypertensive. An angiotensin-converting enzyme (ACE) inhibitor.
-
Therapeutic Function
Antihypertensive
-
Clinical Use
Angiotensin converting enzyme inhibitor:HypertensionHeart failure
-
Drug interactions
Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect.Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDsAntihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARBs and
aliskiren.Bee venom extract: possible severe anaphylactoid
reactions when used togetherCiclosporin: increased risk of hyperkalaemia and
nephrotoxicity.Cytotoxics: increased risk of angioedema with
everolimus.Diuretics: enhanced hypotensive effect;hyperkalaemia with potassium-sparing diureticsESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.Gold: flushing and hypotension with sodium
aurothiomalate.Lithium: reduced excretion, possibility of enhanced
lithium toxicity.Potassium salts: increased risk of hyperkalaemiaTacrolimus: increased risk of hyperkalaemia and
nephrotoxicity.
